valu usd unless otherwis note
strong start revis guidanc appear
view signific upsid segment overcam
soft consum result organ revenu growth
twice estim medic devic also slightli better
estim manag remain commit goal set
segment may busi review increas
estim revenu ep take price target
deliv anoth quarter revenu upsid seventh
row strength ww revenu y/
organ estim upsid came almost
entir segment exclud prior period
adjust contribut ww pharmaceut revenu
growth segment revenu increas y/i also
exclud sale zytiga remicad ww
segment revenu increas mid-teen key growth brand
pharmaceut revenu grew doubl digit fifth straight
comp easi organ growth
revis guidanc organ revenu growth appear
conserv bp increas prior forecast
revenu upsid vs estim alon add bp jnj
revenu growth thu forecast balanc year
rang prior guidanc even assum bigger declin
 zytiga sale deceler medic devic comp
get tougher revis revenu guidanc appear conserv
guidanc report revenu remain
increas estim fx headwind bp
ep guidanc narrow revis guidanc
absorb fx impact wors dilut
auri health transact close april increas
estim incom help
off-set headwind report signific gain advanc
steril product transact estim howev
compani typic adjust discretionari spend mitig
impact larg one-tim gain ep
new revenu ep estim
guidanc high end guidanc estim three
segment pharmaceut cc medic devic
cc adjust diabet asp busi
consum cc intern pharmaceut busi
continu perform past quarter believ
revenu estim go higher price target share increas
old impli price-to-earnings multipl ep
estim consensu
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
forecast ww organ revenu growth
forecast take account signific
sale eros zytiga besid biosimilar competit
remicad gener eros brand base
prescript trend key growth brand strength
outsid medic devic
gradual improv medic devic believ
scope upward revis guidanc
mega-blockbust
contribut new product main growth driver
segment mega-blockbust
brand ww annual peak sale potenti billion
stelara imbruvica darzalex xarelto invega
sustenna/trinza estim ww sale
mega-blockbust increas high-teen led
stelara imbruvica darzalex new brand tremfya
erleada contribut billion sale
estim recent approv spravato esketamin
balversa erdafitnib ad two new growth driver
set goal grow market
medic devic end-market annual
growth rate around certain end-market
vision electrophysiolog advanc surgeri
grow line market compens slower-
qualiti improv adapt busi
model chang environ element
strategi achiev goal
bloomberg capit market estim upside/downside/target
arriv price target use sum-of-the-
part sotp price-to-earnings analysi valu three segment
medic devic consum separ
base peer group multipl base case estim
assum mid-single-digit oper growth
exclud zytiga margin expans share buyback
price target impli price-to-earnings multipl
ep estim y/i
 stronger growth medic
devic segment lift revenu growth basi point
vs base case estim restructur portfolio
ration lead superior oper leverag rel
base case scenario pharmaceut price rhetor
lead legisl chang govern
negoti price pharma compani upsid
scenario impli price-to-earnings multipl ep
estim y/i assumpt
aggress eros remicad zytiga
brand biosimilar gener competit lack
 depress revenu growth neg
downward pressur multipl downsid
scenario impli price-to-earnings multipl y/i
ep estim assumpt
price target base sum-of-the-part sotp analysi target price-to-earnings
multipl base year medic devic consum segment
respect correspond peer group multipl
assign premium segment superior
underli growth outlook rel market growth estim next year
pharmaceut segment contribut toward price target medic devic
consum price target impli blend price-to-earnings multipl ep estim
y/i slight discount price-to-earnings ntm averag price target
support outperform rate share
risk rate price target
face risk typic global diversifi healthcar compani includ
slump navig fda may risk price target rate
johnson johnson one largest diversifi healthcar busi
world oper compani encompass broad rang product across
healthcar field compani world-wide busi divid three main segment
medic devic diagnost sale consum
